Adipogen/Fumitremorgin C/BVT-0189-C250/250 µg
商品编号：
BVT-0189-C250
品牌：
Adipogen Inc
市场价：
¥1600.00
美元价：
960.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | FTC;Tryptoquivaline |
| ProductType | Chemical |
| Properties | |
| Formula | C22H25N3O3 |
| MW | 379.5 |
| CAS | 118974-02-0 |
| Source/HostChemicals | IsolatedfromAspergillusfumigatus. |
| PurityChemicals | ≥98%(HPLC) |
| Appearance | Whitetolightbrownpowder. |
| Solubility | SolubleinDMSO,methanol,acetone,DMForchloroform. |
| Identity | Determinedby1H-NMR. |
| Declaration | ManufacturedbyBioViotica. |
| OtherProductData | Aconcentrationof1mg/mlisrecommendedforstocksolutions. |
| InChiKey | DBEYVIGIPJSTOR-FHWLQOOXSA-N |
| ShippingandHandling | |
| Shipping | AMBIENT |
| ShortTermStorage | +4°C |
| LongTermStorage | +4°C |
| HandlingAdvice | Protectfromlightwheninsolution. |
| Use/StABIlity | Stableforatleast1yearafterreceiptwhenstoredat+4°C. Afterreconstitutionprotectfromlightat-20°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
- Mycotoxin.
- Cytotoxic.
- Tremorgenic.
- Potentandspecificinhibitorofthebreastcancerresistanceprotein(BCRP;ABCG2).
- ReversesmultidrugresistancemediatedbyBCRPandincreasescytotoxicityofseveralanticanceragentsinvitro.
ProductReferences
- MycotoxinsproducedbyAspergillusfumigatusspeciesisolatedfrommoldedsilage:R.J.Cole,etal.;J.Agric.FoodChem.25,826(1977)
- Novelmammaliancellcycleinhibitors,tryprostatinsA,BandotherdiketopiperazinesproducedbyAspergillusfumigatus.I.Taxonomy,fermentation,isolationandBIOLOGicalproperties:C.B.Cui,etal.;J.Antibiot.49,527(1996)
- Reversalofanovelmultidrugresistancemechanisminhumancoloncarcinomacellsbyfumitremorgin:S.K.Rabindran,etal.;CancerRes.58,5850(1998)
- FumitremorginCreversesmultidrugresistanceincellstransfectedwiththebreastcancerresistanceprotein.:S.K.Rabindran,etal.;CancerRes.60,47(2000)
- Characterizationofdrugtransport,ATPhydrolysis,andnucleotidetrappingbythehumanABCG2multidrugtransporter.Modulationofsubstratespecificitybyapointmutation.:Ozvegy,etal.;J.Biol.Chem.277,47980(2002)
- Theroleofbreastcancerresistanceproteininacutelymphoblasticleukemia:S.L.Plasschaert,etal.;Clin.CancerRes.9,5171(2003)
- Plasmapharmacokineticsandtissuedistributionofthebreastcancerresistanceprotein(BCRP/ABCG2)inhibitorfumitremorginCinSCIDmicebearingT8tumors:T.S.Garimella,etal.;CancerChemother.Pharmacol.55,101(2005)
- Histonedeacetylaseinhibitorsinduceaverybroad,pleiotropicanticancerdrugresistancephenotypeinacutemyeloidleukemiacellsbymodulationofmultipleABCtransportergenes:S.Hauswald,etal.;Clin.CancerRes.15,3705(2009)
- Specificinhibitorsofthebreastcancerresistanceprotein(BCRP):A.Pick,etal.;ChemMedChem5,1498(2010)
- DifferentialinhibitionofmurineBcrp1/Abcg2andhumanBCRP/ABCG2bythemycotoxinfumitremorginC:L.Gonzales-Lobato,etal.;Eur.J.Pharmacol.644,41(2010)
- Cytotoxiccompoundsfromthemarine-derivedfungusAspergillussp.recoveredfromthesedimentsoftheBraziliancoast:N.N.Saraiva,etal.;Nat.Prod.Res.29,1545(2014)
- Cross-drugresistancetosunitinibinducedbydoxorubicininendothelialcells:H.L.Huang,etal.;Oncol.Lett.9,1287(2015)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
